Anti-VEGF antibodies and uses thereof
View Patent ↗Provided are monoclonal antibodies and antigen binding fragments thereof that specifically bind vascular endothelial growth factor (VEGF). The anti-VEGF monoclonal antibodies block VEGF binding to its receptors (e.g., VEGFR1 and/or VEGFR2) and prevent phosphorylation of VEGFR2 by VEGF. Also provided are methods of using the monoclonal anti-VEGF antibodies for treatment of disease, including cancer.
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to human VEGF, wherein the variable heavy chain domain (VH) of said antibody or antigen-binding fragment thereof comprises a Kabat heavy chain complementarity determining region-3 (VH-CDR3) amino acid sequence identical to SEQ ID NO:5, a Chothia-Kabat heavy chain complementarity determining region-1 (VH-CDR1) amino acid sequence identical to SEQ ID NO:3, a Kabat heavy chain complementarity determining region-2 (VH-CDR2) amino acid sequence identical to SEQ ID NO:4; and a variable light chain domain (VL) of said antibody or antigen-binding fragment thereof comprises a Kabat light chain complementarity determining region-1 (VL-CDR1) amino acid sequence identical to SEQ ID NO:6, a Kabat light chain complementarity determining region-2 (VL-CDR2) amino acid sequence identical to SEQ ID NO:7, and a Kabat light chain complementarity determining region-3 (VL-CDR3) amino acid sequence identical to SEQ ID NO:8.
2. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said antibody is MAb 7392 or an antigen-binding fragment thereof or wherein said antibody or fragment thereof competitively inhibits reference monoclonal antibody MAb 7392 from specifically binding to VEGF.
3. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the VH of said antibody or fragment thereof comprises the amino acid sequence of SEQ ID NO:1.
4. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the VL of said antibody or fragment thereof comprises the amino acid sequence of SEQ ID NO:2.
5. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the VH and VL of said antibody or fragment thereof comprise amino acid sequences identical to SEQ ID NO:1 and SEQ ID NO:2, respectively.
6. The antibody or antigen-binding fragment thereof according to claim 1 , which is an Fab fragment, an F(ab) 2 fragment, an Fv fragment, or a single chain antibody.
7. The antibody or antigen-binding fragment thereof according to claim 1 , which comprises a light chain constant region selected from the group consisting of a human kappa constant region and a human lambda constant region.
8. The antibody or antigen-binding fragment thereof according to claim 1 , which comprises a heavy chain constant region or a fragment thereof.
9. The antibody or antigen-binding fragment thereof according to claim 8 , wherein said heavy chain constant region or fragment thereof is human IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgE or IgD.
10. The antibody or antigen-binding fragment thereof according to claim 1 , which inhibits VEGF from binding to a VEGF receptor.
11. The antibody or antigen-binding fragment thereof according to claim 10 , wherein said VEGF receptor is selected from the group consisting of VEGFR1 and VEGFR2.
12. The antibody or antigen-binding fragment thereof according to claim 1 , which inhibits phosphorylation of VEGFR2 by VEGF.
13. The antibody or antigen-binding fragment thereof according to claim 1 , further comprising a heterologous polypeptide fused thereto.
14. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said antibody or fragment thereof is further conjugated to at least one agent selected from the group consisting of a cytotoxic agent, a therapeutic agent, a cytostatic agent, a biological toxin, a prodrug, an enzyme, a lipid, a biological response modifier, a lymphokine, a heterologous antibody or fragment thereof, a detectable label, and polyethylene glycol (PEG).
15. The antibody or antigen-binding fragment thereof according to claim 14 , wherein said at least one cytotoxic agent is selected from the group consisting of a radionuclide, a biotoxin, and an enzymatically active toxin.
16. The antibody or antigen-binding fragment thereof according to claim 14 , wherein said at least one detectable label is selected from the group consisting of an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent label, and a radioactive label.
17. A composition comprising the antibody or antigen-binding fragment thereof according to claim 1 , and a carrier.
18. The composition of claim 17 , wherein said carrier is selected from the group consisting of saline, buffered saline, dextrose, water, and glycerol.
19. A method for neutralizing VEGF in an animal, said method comprising administering to said animal a composition comprising:
(a) the isolated antibody or antigen-binding fragment thereof of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
20. A method for treating a cancer in an animal in need of treatment, said method comprising administering to said animal a composition comprising:
(a) the isolated antibody or antigen-binding fragment thereof of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
21. A method for inhibiting angiogenesis in an animal in need of treatment for cancer, said method comprising administering to said animal a composition comprising:
(a) the isolated antibody or antigen-binding fragment thereof of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
22. The method of claim 20 , wherein said cancer is a solid tumor.
23. The method of claim 20 , wherein said cancer is selected from the group consisting of colorectal cancer, lung cancer, renal cell carcinoma, breast cancer, non-small cell lung cancer, and glioblastoma.
24. The method of claim 20 , wherein said cancer is metastatic.
25. The method of claim 20 , wherein said cancer is non-resectable.
26. The method according to claim 20 , wherein said method further comprises administering to said animal at least one additional therapy.
27. The method of claim 26 , wherein said at least one additional therapy is selected from the group consisting of radiation therapy and chemotherapy.
28. The method of claim 27 , wherein said at least one additional therapy is a chemotherapy selected from the group consisting of taxane, paclitaxel, carboplatin, 5-flurouracil, leucovorin, capecitabine, oxaliplatin, and irinotecan.
29. The method of claim 20 , wherein said antibody or antigen-binding fragment thereof inhibits VEGF binding to a VEGF receptor.
30. The method of claim 29 , wherein said VEGF receptor is VEGFR1 or VEGFR2.
31. The method of claim 20 , wherein said antibody or antigen-binding fragment thereof inhibits phosphorylation of VEGFR2 by VEGF.
32. The method of claim 20 , wherein said animal is a human.
33. The antibody or antigen-binding fragment according to claim 1 , wherein the light chain constant region is a human kappa constant region.
34. The antibody or antigen-binding fragment according to claim 9 , wherein the heavy chain constant region or fragment thereof is human IgG1.